<DOC>
	<DOCNO>NCT00957749</DOCNO>
	<brief_summary>Molybdenum Cofactor Deficiency Type A ( MoCD ) rare autosomal recessive disorder essentially fatal early life . Naturally occur cPMP present body healthy normal individual . It process molybdopterin , process molybdenum cofactor . Molybdenum cofactor essential function important enzyme . There currently treatment MoCD , affect infant develop severe neurological damage often result infant death . This study first clinical trial investigate potential replacement cPMP infant MoCD Type A . The safety , tolerability , pharmacodynamics daily intravenous administration cPMP 3 month determine .</brief_summary>
	<brief_title>Study cPMP ( Precusor Z ) Treat Molybdenum Cofactor Deficiency ( MoCD ) Type A</brief_title>
	<detailed_description />
	<mesh_term>Metal Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<criteria>Neonate infant , less 6 week time diagnosis , age le 8 week start treatment study medication . It important diagnose condition initiate treatment soon birth possible . Documented diagnosis molybdenum cofactor deficiency ( MoCD ) Type A base absence cPMP presence sulfite ssulfocysteine urine , absence urothione urine genetic analysis show mutation MOCS1 gene A parent legal guardian voluntarily provide write informed consent participate study comply study procedure . Approval study protocol local HE / IRB government regulatory authority ( applicable ) MoCD Type B ( MOCS2 mutation ) Type C ( gephyrin gene mutation ) Sulfite oxidase deficiency Patients old 6 week time diagnosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Weeks</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>